原发性肺黏液腺癌的研究进展

The research progress of primary pulmonary mucinous adenocarcinoma

原发性肺黏液腺癌多发生于成年男性,是发病率低的肺腺癌的一种亚型,因其无明显临床特异性,容易造成误诊,给患者造成不良的预后,因此我们需要进一步了解该种疾病并通过多种手段早期确诊。手术治疗仍然是该病的首选方式,不仅可以切除病灶还可以进一步病理确诊、基因检测、肿瘤分期及预后判定,以及为后续化疗做准备。最近几年,随着基因技术的不断发展与创新,发现该疾病的发生与KRAS基因突变、ALK基因重排以及其相关信号通路有关。相关基因突变和信号通路可成为治疗该病的靶点,这为新的靶向药物的研制提供了多种思路。但是仍然有许多问题需要进一步研究,包括原发性肺黏液腺癌的标准化疗方案、靶向药物的耐药问题以及新的KRAS抑制剂的研制。本文从原发性肺黏液腺癌的定义和发病机制、诊断以及最新的一些治疗手段研究进行综述。

Primary pulmonary mucinous adenocarcinoma with a low incidence,a subtype of lung adenocarcinoma,occurs in adult males because of its no significant clinical specificity,likely to cause misdiagnosis,and patients with adverse prognosis. Thus,we need further to understand this disease and early diagnosis through a variety of methods as soon as possible. Surgical treatment is still the preferred mode of this disease. With addition to resecting lesions,it is also further pathological diagnosis,gene testing,tumor staging and prognosis as well as preparation for following-up chemotherapy. In recent years,with the continuous development of genetic technology and innovation,the occurrence of this disease has been found to be related to KRAS gene mutation,ALK gene rearrangement and its related signal pathway. Related gene mutations and signaling pathways can serve as a target for the treatment of this disease,which provides a variety of ideas for the development of new targeted drugs. However,there are still many problems that need further study,including standard chemotherapy for primary pulmonary mucinous adenocarcinoma,drug resistance to targeted drugs,and the development of new KRAS inhibitors. This article reviews the definition of primary pulmonary mucinous adenocarcinoma and pathogenesis,diagnosis and some of the latest treatment methods.